Clinical Trials in the USA / NCT07092254
Active, not recruiting
Observational
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
NCT07092254 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Triple Negative Breast Cancer
Investigational drug(s) / intervention(s)
No drug
No drug: No study drug will be administered in this non-interventional study.
Study summary
This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of therapy, and outcomes to contextualize findings of TROPION-Breast02 and TROPION-Breast05 in selected settings outside the United States (US), including Canada, the United Kingdom (UK), France, and Spain.
Eligibility
Patients meeting the following criteria will be included in the study:
* Histologically or cytologically documented diagnosis of HR-negative and HER2-negative locally recurrent inoperable TNBC (i.e., cannot be treated with curative intent) or advanced/metastatic TNBC from 1 January 2020 to 31 March 2024
* Negative for estrogen receptor with \< 1% of tumor cells positive for estrogen receptor (ER) on immunohistochemistry (IHC)
* Negative for progesterone receptor with \< 1% of tumor cells positive for progesterone receptor on IHC
* Negative for HER2 with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridization per the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) HER2 guideline
* The test documented closest to the diagnosis date should be used as the reference
* Aged at least 18 years upon diagnosis of advanced/metastatic TNBC
* Known vital status (alive or deceased) as of last available follow-up date documented within the medical record
Patients meeting any of the following exclusion criteria will not be eligible for the study:
* Diagnosis of other prior primary cancers or malignancies (except nonmelanoma skin cancer) unless curatively treated with no evidence of disease for at least 3 years before diagnosis of advanced/metastatic TNBC
* Ever received treatment as part of any clinical trial of an investigational product for cancer
* No available medical record entry in the 90 days before or after diagnosis of advanced/metastatic TNBC
Primary outcome measure(s)
- Treatment sequencing before the diagnosis of advanced, metastatic TNBC (i.e., all treatments received for early TNBC if initially diagnosed with earlier-stage disease) — From date of initial diagnosis of early TNBC (if applicable) until diagnosis date of advanced, metastatic TNBC, up to approximately 15 months
Treatment sequencing Includes broad categories for surgery, radiotherapy, adjuvant and neoadjuvant chemotherapy, immunotherapy, and start and stop dates of systemic therapy. - Treatment sequencing on or after the diagnosis date for advanced, metastatic TNBC — From date of initial diagnosis of advanced, metastatic TNBC until end of follow-up, up to approximately 15 months
Treatment sequencing Includes broad categories for surgery, radiotherapy, adjuvant and neoadjuvant chemotherapy, immunotherapy, and start and stop dates of systemic therapy. - Real-world disease-free interval (rwDFI) — From the completion of treatment with curative intent (either date of breast tumor surgery or date of last dose of systemic therapy (whichever occurred last) and the first local or distant disease recurrence date, up to approximately 15 months
Real-world disease-free interval (rwDFI) is assessed from the completion of treatment with curative intent (either date of primary breast tumor surgery or date of last dose of systemic anticancer therapy \[not including endocrine therapy\], whichever occurred last) and the first documented local or distant disease recurrence date - Clinician-defined real-world progression-free survival (rwPFS) — From the start of each line of therapy until end of follow up, up to approximately 15 months
Clinician-defined rwPFS is assessed from the index date and from the start of each line of therapy. - Overall survival — From the start of each line of therapy until end of follow-up, up to approximately 15 months
OS is assessed from the index date and from the start of each line of therapy. - Occurrence of clinical events of interest — From the start of each line of therapy until end of follow-up, up to approximately 15 months
The occurrence of the following clinical events of interest will be assessed during each therapy line: Oral mucositis/stomatitis, Interstitial lung disease/pneumonitis, OSE, Diarrhea, Nausea/vomiting, Anemia, Neutropenia, Febrile neutropenia, Leukopenia, Lymphopenia, Thrombocytopenia.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Basking Ridge | New Jersey |
More Daiichi Sankyo trials in the USA
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Active, not recruiting
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Active, not recruiting
Other trials for the same condition
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07092254 on ClinicalTrials.gov ↗ ← All trials in the USA